Clinicopathologic and Molecular Characterization of Epstein-Barr Virus-positive Plasmacytoma.
Journal
The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904
Informations de publication
Date de publication:
01 10 2022
01 10 2022
Historique:
pubmed:
3
6
2022
medline:
21
9
2022
entrez:
2
6
2022
Statut:
ppublish
Résumé
Epstein-Barr virus (EBV)-positive plasmacytoma is a rare plasma cell neoplasm. It remains unclear whether EBV-positive plasmacytoma represents a distinct entity or a variant of plasmacytoma. It shares morphologic features with plasmablastic lymphoma (PBL) and may cause diagnostic uncertainty. To better understand EBV-positive plasmacytoma and explore diagnostic criteria, this study describes 19 cases of EBV-positive plasmacytoma, compared with 27 cases of EBV-negative plasmacytoma and 48 cases of EBV-positive PBL. We reviewed the clinicopathologic findings and performed immunohistochemistry, in situ hybridization for EBV, fluorescence in situ hybridization for MYC , and next-generation sequencing. We found that 63.2% of patients with EBV-positive plasmacytoma were immunocompromised. Anaplastic features were observed in 7/19 cases. MYC rearrangement was found in 25.0% of them, and extra copies of MYC in 81.3%. EBV-positive and EBV-negative plasmacytomas possessed similar clinicopathologic features, except more frequent cytologic atypia, bone involvement and MYC aberrations in the former group. The survival rate of patients with EBV-positive plasmacytoma was comparable to that of patients with EBV-negative plasmacytoma. In comparison to PBL, EBV-positive plasmacytoma is less commonly associated with a "starry-sky" appearance, necrosis, absence of light chain expression, and a high Ki67 index (>75%). The most recurrently mutated genes/signaling pathways in EBV-positive plasmacytoma are epigenetic regulators, MAPK pathway, and DNA damage response, while the most frequently reported mutations in PBL are not observed. Collectively, EBV-positive plasmacytoma should be regarded as a biological variant of plasmacytoma. Thorough morphologic examination remains the cornerstone for distinguishing EBV-positive plasmacytoma and PBL, and molecular studies can be a valuable complementary tool.
Identifiants
pubmed: 35650679
doi: 10.1097/PAS.0000000000001923
pii: 00000478-202210000-00005
pmc: PMC9481705
mid: NIHMS1806900
doi:
Substances chimiques
Ki-67 Antigen
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1364-1379Subventions
Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest and Source of Funding: This work was supported by funding from the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, NIH. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
Références
McKenna R, Kyle RA, Kuehl WM, et al. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. Plasma cell neoplasms. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Revised, 4th ed. Lyon, France: International Agency for Research on Cancer; 2017:250–253.
McKenna RW, Kroft SH, Linden MA Jaffe E, Arber D, Campo E, Quintanilla-Fend L, Orazi A. Plasma cell neoplasms. Hematopathology, 2nd ed. Philadelphia, PA: Elsevier; 2016:496–498.
Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34:1686–1694.
Garcia-Reyero J, Martinez Magunacelaya N, Gonzalez de Villambrosia S, et al. Genetic lesions in MYC and STAT3 drive oncogenic transcription factor overexpression in plasmablastic lymphoma. Haematologica. 2021;106:1120–1128.
Montes-Moreno S, Martinez-Magunacelaya N, Zecchini-Barrese T, et al. Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. Mod Pathol. 2017;30:85–94.
Campo E, Swerdlow SH, Harris NL Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. Plasmablastic lymphoma. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon, France: International Agency for Research on Cancer; 2017:321–322.
Castillo JJ, Furman M, Beltran BE, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012;118:5270–5277.
Loghavi S, Khoury JD, Medeiros LJ. Epstein-Barr virus-positive plasmacytoma in immunocompetent patients. Histopathology. 2015;67:225–234.
He L, Li Z, Fan X, et al. Epstein-Barr virus-positive plasmacytoma in immunocompetent patients: a diagnostic dilemma. Int J Clin Exp Pathol. 2020;13:582–586.
Delecluse HJ, Anagnostopoulos I, Dallenbach F, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413–1420.
Yan J, Wang J, Zhang W, et al. Solitary plasmacytoma associated with Epstein-Barr virus: a clinicopathologic, cytogenetic study and literature review. Ann Diagn Pathol. 2017;27:1–6.
Oaxaca G, Coffey A, Gannon F, et al. Low-grade Epstein-Barr virus positive plasma cell proliferations of precursor plasma cell origin: report of two cases. Int J Clin Exp Med. 2017;10:11073–11078.
Qing X, Sun N, Chang E, et al. Plasmablastic lymphoma may occur as a high-grade transformation from plasmacytoma. Exp Mol Pathol. 2011;90:85–90.
Li YJ, Li JW, Chen KL, et al. HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases. Blood Res. 2020;55:49–56.
Colomo L, Loong F, Rives S, et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol. 2004;28:736–747.
Trappe R, Zimmermann H, Fink S, et al. Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica. 2011;96:1067–1071.
Mariani R, King RL, Liu H. EBV-positive plasmacytomas involving a nasopharyngeal angiofibroma in an adolescent. Pediatr Dev Pathol. 2021;24:264–268.
Shao H, Xi L, Raffeld M, et al. Nodal and extranodal plasmacytomas expressing immunoglobulin A: an indolent lymphoproliferative disorder with a low risk of clinical progression. Am J Surg Pathol. 2010;34:1425–1435.
Ramis-Zaldivar JE, Gonzalez-Farre B, Nicolae A, et al. MAP-kinase and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica. 2021;106:2682–2693.
Thumallapally N, Meshref A, Mousa M, et al. Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer. 2017;17:13.
Liu Z, Filip I, Gomez K, et al. Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway. Blood Cancer Discov. 2020;1:112–125.
Frontzek F, Staiger AM, Zapukhlyak M, et al. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun. 2021;12:5183.
Chang ST, Liao YL, Lu CL, et al. Plasmablastic cytomorphologic features in plasma cell neoplasms in immunocompetent patients are significantly associated with EBV. Am J Clin Pathol. 2007;128:339–344.
Yan B, Tan SY, Yau EX, et al. EBV-positive plasmacytoma of the submandibular gland--report of a rare case with molecular genetic characterization. Head Neck Pathol. 2011;5:389–394.
Aref S, Goda T, El-Sherbiny M. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors. Hematology. 2003;8:221–228.
Bayer-Garner IB, Sanderson RD, Dhodapkar MV, et al. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol. 2001;14:1052–1058.
Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, et al. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol. 2010;23:991–999.
Hess B, Giri A, Park Y, et al. Outcomes of patients with limited-stage plasmablastic lymphoma [abstract]. 2020. Blood. 2020;136;(suppl 1):15–16.
Vikova V, Jourdan M, Robert N, et al. Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance. Theranostics. 2019;9:540–553.
Desideri E, Cavallo AL, Baccarini M. Alike but different: RAF paralogs and their signaling outputs. Cell. 2015;161:967–970.
Smith G, Bounds R, Wolf H, et al. Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours—implications for personalised cancer medicine. Br J Cancer. 2010;102:693–703.
Naguib A, Wilson CH, Adams DJ, et al. Activation of K-RAS by co-mutation of codons 19 and 20 is transforming. J Mol Signal. 2011;6:2.
Ambrosio MR, De Falco G, Gozzetti A, et al. Plasmablastic transformation of a pre-existing plasmacytoma: a possible role for reactivation of Epstein Barr virus infection. Haematologica. 2014;99:e235–e237.